Pfizer PFE Paxlovid and Comirnaty — Deferred revenues, noncurrent

Similar metrics at other companies

VCYTBiopharmaceutical and other revenue — Deferred Revenue

$700K-58.8%

REGNDeferred revenue, net of current portion

$225.1M+6.3%

SDGROncology, Neurology, and Immunology Product — Deferred Revenue

$2.5M—

SDGRDrug discovery — Deferred revenue, long-term

$52.82M-42.5%

TSLADeferred revenue, net of current portion

$3.85B+6.6%

AMEDeferred revenue, net of current portion

$41.8M+5.3%

Questions, answered.

What is Pfizer's paxlovid and comirnaty — deferred revenues, noncurrent?

Pfizer (PFE) reported paxlovid and comirnaty — deferred revenues, noncurrent of $816M in Q1 2026.

How has Pfizer's paxlovid and comirnaty — deferred revenues, noncurrent changed year-over-year?

Pfizer's paxlovid and comirnaty — deferred revenues, noncurrent decreased by 16.5% year-over-year, from $977M to $816M.

What does paxlovid and comirnaty — deferred revenues, noncurrent mean?

This represents the portion of deferred revenue for specific pharmaceutical products that is expected to be recognized as revenue beyond the next twelve months. It reflects long-term supply agreements or multi-year delivery commitments where the performance obligation extends well into the future. This metric provides insight into the long-term stability of the product segment's revenue stream.